Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.46 |
| ▸ | DRD2 | P14416 | 12/20 | 0.45 |
| ▸ | HTR2A | P28223 | 12/20 | 0.45 |
| ▸ | DRD3 | P35462 | 12/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | SLC9A1 | P19634 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6677973 | 0.88 | DRD2 (0.49) | DRD2HTR2ADRD3SLC9A1 | |
| SCHEMBL8548879 | 0.79 | ADRB1 (0.50) | HTR2C | |
| SCHEMBL614437 | 0.74 | HTR1A (0.46) | HTR2C | |
| SCHEMBL9977563 | 0.73 | DRD2 (0.62) | DRD2HTR2ADRD3 | |
| SCHEMBL24120085 | 0.73 | HTR2C (0.51) | HTR2C | |
| SCHEMBL19699408 | 0.73 | SLC9A1 (0.46) | DRD2HTR2ADRD3SLC9A1 | |
| SCHEMBL19690310 | 0.73 | SLC9A1 (0.46) | DRD2HTR2ADRD3SLC9A1 | |
| SCHEMBL17781855 | 0.73 | SLC9A1 (0.46) | DRD2HTR2ADRD3SLC9A1 | |
| SCHEMBL12081257 | 0.72 | HTR2C (0.47) | HTR2CDRD2HTR2ADRD3 | |
| Hydrochloric Acid SCHEMBL23780213 | 0.71 | HTR2C (0.53) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877778-B2 | Benzofurane compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-11-04 | — | — | US | disclosed |
| EP-2651929-A1 | NOVEL BENZOFURANE COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| CN-103261190-A | Novel benzofurane compounds | HOFFMANN LA ROCHE | 2013-08-21 | — | — | CN | disclosed |
| US-20120157449-A1 | BENZOFURANE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-06-21 | — | — | US | disclosed |
| WO-2012080149-A1 | NOVEL BENZOFURANE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157449-A1 | BENZOFURANE COMPOUNDS | HTR3A, HTR3C, HTR2A | HTR2C 6/4885DRD2 37/4885HTR2A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.